{"id":"1b6f6c8e-f47d-5e32-91ab-a404b483c33d","stable_key":"10629adf-a816-5b7b-82db-a76bfbb946f2:bg-second-trial-not-significant","predicate":"preserves_measured_pool","statement":"Objective response rate based on blinded central radiology review was higher in the BTH1677 arm versus control but the difference between groups was not statistically significant at 60.4% versus 43.5% with P = .2096, all other clinical endpoints also favoured the BTH1677 arm but none statistically differed between arms, and although a higher incidence of Grade 3 or 4 adverse events occurred in the BTH1677 versus control arm at 93.2% versus 66.7% no unexpected adverse events were observed while serious adverse events and discontinuations due to adverse events were lower.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"c79f630e-32c4-5fc6-bc8c-3771ddda8712","mechanism_event_label":"A second trial pointed the same way on every measure and reached statistical significance on none of them.","subject":{"id":"a04b52d4-0af9-594a-bbda-51a16406d235","slug":"imprime-pgg","display_name":"Imprime PGG / BTH1677, a soluble yeast beta-(1->3)/(1->6)-glucan","entity_type_key":"drug"},"object":{"id":"fae8ae7e-3be1-5692-898a-c3790790bfb5","slug":"objective-response-rate","display_name":"Objective tumour response rate","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"c79f630e-32c4-5fc6-bc8c-3771ddda8712","stable_key":"10629adf-a816-5b7b-82db-a76bfbb946f2:bg-second-trial-not-significant-event","event_type":"observed_intervention","label":"A second trial pointed the same way on every measure and reached statistical significance on none of them.","description":"Objective response rate based on blinded central radiology review was higher in the BTH1677 arm versus control but the difference between groups was not statistically significant at 60.4% versus 43.5% with P = .2096, all other clinical endpoints also favoured the BTH1677 arm but none statistically differed between arms, and although a higher incidence of Grade 3 or 4 adverse events occurred in the BTH1677 versus control arm at 93.2% versus 66.7% no unexpected adverse events were observed while serious adverse events and discontinuations due to adverse events were lower.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"ad94cfea-9646-5b72-9c22-9faa10195be5","slug":"progression-free-survival","display_name":"Progression-free survival in high-grade glioma","entity_type_key":"cellular_process"},"role":"secondary_endpoint","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"d3889da6-26a5-53db-8524-995e87aa75ba","slug":"antitumour-monoclonal-antibody","display_name":"Complement-activating antitumour monoclonal antibodies","entity_type_key":"protein"},"role":"backbone_therapy","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"a04b52d4-0af9-594a-bbda-51a16406d235","slug":"imprime-pgg","display_name":"Imprime PGG / BTH1677, a soluble yeast beta-(1->3)/(1->6)-glucan","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"fae8ae7e-3be1-5692-898a-c3790790bfb5","slug":"objective-response-rate","display_name":"Objective tumour response rate","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/glucan-research/29486797.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"7e4ff586490d7fdbefa5e817f7ee8b59c72e666bfb473620331f2fb178f46789\", \"start_char\": 0, \"end_char\": 2024, \"text_sha256\": \"7e4ff586490d7fdbefa5e817f7ee8b59c72e666bfb473620331f2fb178f46789\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Randomised controlled phase II trial with blinded central radiology review as the primary read","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"BTH1677 4 milligrams per kilogram weekly with bevacizumab, carboplatin and paclitaxel against the same backbone alone","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Ninety-two patients randomised 61 to 31, with response read centrally. A higher rate of grade 3 or 4 adverse events occurred on the glucan arm.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair.","comparator":null,"unit":null,"notes":"","entity":{"slug":"beta-glucan","display_name":"Beta-glucan","entity_type_key":"chemical_species"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"A second trial pointed the same way on every measure and reached statistical significance on none of them.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[bg-p29486797] A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer. (2018). https://pubmed.ncbi.nlm.nih.gov/29486797/ DOI: 10.1186/s40425-018-0324-z","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Untreated advanced non-small cell lung cancer","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"d3b6d732-944d-5b97-9013-d4968b036a82","evidence_kind":"source_excerpt","locator":"Lines 320-331","start_line":320,"end_line":331,"excerpt":"### bg-second-trial-not-significant\nObjective response rate based on blinded central radiology review was higher in the BTH1677 arm versus control but the difference between groups was not statistically significant at 60.4% versus 43.5% with P = .2096, all other clinical endpoints also favoured the BTH1677 arm but none statistically differed between arms, and although a higher incidence of Grade 3 or 4 adverse events occurred in the BTH1677 versus control arm at 93.2% versus 66.7% no unexpected adverse events were observed while serious adverse events and discontinuations due to adverse events were lower.\nCondition category: normal\nnutrient_topic: Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair.\nplain_language: A second trial pointed the same way on every measure and reached statistical significance on none of them.\norganism: Human\ntissue_or_cell_type: Untreated advanced non-small cell lung cancer\nexperimental_model: Randomised controlled phase II trial with blinded central radiology review as the primary read\nlimitations: Ninety-two patients randomised 61 to 31, with response read centrally. A higher rate of grade 3 or 4 adverse events occurred on the glucan arm.\nexposure: BTH1677 4 milligrams per kilogram weekly with bevacizumab, carboplatin and paclitaxel against the same backbone alone\nevidence_span: {\"source_cache\": \"artifacts/glucan-research/29486797.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"7e4ff586490d7fdbefa5e817f7ee8b59c72e666bfb473620331f2fb178f46789\", \"start_char\": 0, \"end_char\": 2024, \"text_sha256\": \"7e4ff586490d7fdbefa5e817f7ee8b59c72e666bfb473620331f2fb178f46789\"}\n[bg-p29486797] A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer. (2018). https://pubmed.ncbi.nlm.nih.gov/29486797/ DOI: 10.1186/s40425-018-0324-z","model_system":"Randomised controlled phase II trial with blinded central radiology review as the primary read","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [bg-p29486797] A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer. (2018). https://pubmed.ncbi.nlm.nih.gov/29486797/ DOI: 10.1186/s40425-018-0324-z","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"74dc223d-8289-57bf-a731-d220fa017c1e","stable_key":"import-10629adf-a816-5b7b-82db-a76bfbb946f2","title":"Beta-glucan: a structural family rather than an agent, what decides whether a bound glucan actually signals, the complement route that a cereal and a yeast preparation share, and the unequal human evidence behind each (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"7c62f2d2f8d99b650e6dc26a505b0f053ae1c8bdb38099d4dfc0771f65287461","revision_id":"a53bb794-0a4b-525d-9cf7-22b46a5403b0","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}